

Director/PDMR Shareholding

RNS Number : 6764Y
Novacyt S.A.
30 March 2026



Novacyt S.A.

("Novacyt" or the "Company")

Director/PDMR Shareholding

Paris, France, and Manchester, UK - 30 March 2026 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), the international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that it has been notified that, on 26 and 27 March 2026, the following Directors purchased ordinary shares of €1/15 each in the Company (the "Ordinary Shares"):

Director	Title	Number of Ordinary Shares purchased	Average price paid per Ordinary Share	Resultant beneficial holding	% of issued share capital
Lyn Rees	CEO	73,379	€0.3899	73,379	0.00%
John Brown	Chairman	73,762	€0.3899	73,762	0.00%
Ian Gilham	NED	28,750	£0.34415	28,750	0.00%

Contacts

Novacyt SA

<https://novacyt.com/investors>

Lyn Rees, Chief Executive Officer

Via Walbrook PR

Steve Gibson, Chief Financial Officer

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)	+44 (0)20 3470 0470
--	----------------------------

Matthew Johnson / Charlie Bouverat (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking)
--

Singer Capital Markets (Joint Broker)	+44 (0) 20 7496 3000
--	-----------------------------

Phil Davies / James Fischer / Samed Ethem

Allegra Finance (French Listing Sponsor) Rémi Durgetto / Yannick Petit	+33 (1) 42 22 10 10 r.durgetto@allegrafinance.com / y.petit@allegrafinance.com
--	---

Walbrook PR (Financial PR & IR) Paul McManus / Lianne Applegarth Alice Woodings	+44 (0)20 7933 8780 or novacyt@walbrookpr.com +44 (0)7980 541 893 / +44 (0)7584 391 303 +44 (0)7407 804 654
--	---



About Novacyt Group (www.novacyt.com)

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

Clinical	Broad portfolio of human clinical <i>in vitro</i> diagnostic products, workflows and services focused on three therapeutic areas: · Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests · Precision Medicine: DPYD genotyping assay · Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel
Instrumentation	Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including: · Ranger® Technology: automated DNA sample preparation and target enrichment technology · genesig q16 and q32 real-time quantitative PCR (qPCR) instruments
Research Use Only	Range of services for the life sciences industry: · Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry · Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

Novacyt is headquartered in Le Vésinet in France with offices in the UK (Manchester), Singapore, the US and Canada and has a commercial presence in over 65 countries, including Australia, following the recent acquisition of Southern Cross Diagnostics in March 2026, which has opened new distribution channels to the life sciences and diagnostics industries in the territory and the wider Asia-Pacific region. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

For more information, please refer to the website: www.novacyt.com

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1. Details of the person discharging managerial responsibilities / person closely associated

Name a) 1) Lyn Rees 2) John Brown 3) Ian Gilham	1) CEO 2) Chairman 3) NED
2. Reason for the Notification	
a) Position/status	See 1(a) - classified as a PDMR of the Company
b) Initial notification/ Amendment	Initial Notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a) Name	Novacyt S.A.
b) LEI	213800BWAC2BF295EG28
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a) Description of the Financial instrument, type of instrument	ordinary shares of €1/15 each
Identification code	FR0010397232
b) Nature of the transaction	Acquisition of Ordinary Shares

Price	Volume
€0.3817	15,149
€0.3919	56,438
€0.3945	1,792

Price(s) and volume(s)

1) Lyn Rees

Price	Volume
€0.3817	15,228
€0.3919	56,732
€0.3950	1,802

c) 2) John Brown

3) Ian Gilham

Price	Volume
£0.34415	28,750

		Price	Volume
		€0.3899	73,379
Aggregated information:			
· Aggregated volume			
· Price			
d)	1) Lyn Rees	Price	Volume
	2) John Brown	€0.3899	73,762
	3) Ian Gilham		
		Price	Volume
		£0.34415	28,750
e) Date of the transaction		1 & 2) 26 and 27 March 2026 3) 27 March 2026	
f) Place of the transaction		1 & 2) Euronext and 3) AIM	

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHWPUMPWUPQGWU